nature research

| Corresponding author(s): | Maria Lluch-Senar & Luís Serrano |
|----------------------------|----------------------------------|
| Last updated by author(s): | Sep 30, 2022 |

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| ٠. | | | |
|----|-----|-----|-----|
| Sτ | `at | ict | ICC |

| Sta | atistics | | |
|---|--|--|--|
| For | all statistical ar | nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. | |
| n/a | Confirmed | | |
| | The exact | sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement | |
| | A stateme | ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly | |
| | The statis Only comm | tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section. | |
| | A description of all covariates tested | | |
| | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons | | |
| | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) | | |
| For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable. | | | |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings | | | |
| | For hierar | chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes | |
| | Estimates | of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated | |
| | ' | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. | |
| So | ftware an | d code | |
| Poli | cy information | about availability of computer code | |
| D | ata collection | No software was used | |
| D | ata analysis | goeBURST algorithm, G*Power software (3.1), StatsDirect software (3.1.8) or GraphPad Prism (8.0.1) | |
| | | g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. | |
| Da | nta | | |

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that the data supporting the findings of this study are available within the paper.

| Field-spec | ific reporting | |
|-----------------------------|--|---|
| Please select the one | below that is the best fit for your research. If y | ou are not sure, read the appropriate sections before making your selection |
| X Life sciences | Behavioural & social sciences | Ecological, evolutionary & environmental sciences |
| For a reference copy of the | document with all sections, see nature.com/documents/nr- | reporting-summary-flat.pdf |

Life sciences study design

Replication

Blinding

All studies must disclose on these points even when the disclosure is negative.

Sample size Sample size was calculated using G*power software with the fol

Sample size was calculated using G*power software with the following parameter: error α :0.05; potency 1- β :0.8, values for parameter "final score of pulmonary lesions" based in previous experiment (average ±SD) 12.1±6 y 5.8±2.5, obtaining as a output n=5 mice per group.

Data exclusions In the ex-vivo assays with sections of endotracheal tubes, one control sample was discarded because no P. aeruginosa counts could be

obtained due to overgrowth of Proteus species.

All the in vitro assays were carried out using al least triplicate samples; all the assays were reproduced at least three independent times. In vivo assays with mice were performed with at least 6 animals in each experimental group, and all attempts at replication were successful. For any other epxeriments, independent experiments with triplicate samples were always performed.

Randomization
All the mice in the in vivo are commercial inbred strains assay, carrying the same genetic background. Hence, the animals were allocated randomly in each group. In the assays with ex-vivo endotracheal tubes, section of each tube were allocated randomly into experimental groups.

The analysis of the ex-vivo samples (i.e. histopathology analysis) was analysed by a pathologist that did not know the ID of the samples. For experiments other than histopathology analysis, the investigators were also blinded to group allocation during data collection and/or analysis (i.e. animal health scoring during survival curves, counting of bacterial CFUs on plates). No blinding was required when objective data (i.e. absorbance values provided by plate reader, animals weights, Ct values from RT-qPCR) were analysed and plotted on graphs.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------------------------|
| n/a Involved in the study | n/a Involved in the study |
| Antibodies | ChIP-seq |
| Eukaryotic cell lines | Flow cytometry |
| Palaeontology and archaeology | MRI-based neuroimaging |
| Animals and other organisms | ' |
| Human research participants | |
| Clinical data | |
| Dual use research of concern | |
| ' | |

Animals and other organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research

Laboratory animals

CD1 mice (female and male, 18–22 g, aged 4-6 weeks) were purchased from Charles River Laboratories (France)

Wild animals

The study did not involve wild animals

Field-collected samples The study did not involve samples collected from the fied

Ethics oversight

- In vivo experiments produced by University of Navarra (Spain): Animal handling and procedures were in accordance with the current European (Directive 86/609/EEC) and National (Real Decreto 53/2013) legislations, following the FELASA and ARRIVE

current European (Directive 86/609/EEC) and National (Real Decreto 53/2013) legislations, following the FELASA and ARRIVE guidelines and with the approval of the Universidad Pública de Navarra (UPNa) Animal Experimentation Committee (Comité de Ética, Experimentación Animal y Bioseguridad) and the local Government authorization.

- In vivo experiments produced by Evotec (UK): all in vivo animal studies were performed in the UK under the UK Home Office License PA67E0BAA, with the clearance of the local ethical committee Animal Welfare and Ethical Review Body.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about <u>studies involving human research participants</u>

Population characteristics Endotracheal tubes were obtained from mediane

Endotracheal tubes were obtained from mechanically ventilated patients admitted to an Intensive Care Medicine Unit (Hospital Clinic of Barcelona) with ventilator associated pneumonia (VAP) due to P. aeruginosa

Recruitment September 2015 to December 2017

Ethics oversight Collection R190311-203; HCB/2019/0262. Approved by the Ethical Committee for Research in Medicines, Hospital Clinic of Barcelona, Spain.

Note that full information on the approval of the study protocol must also be provided in the manuscript.